Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy

Recipients of chimeric antigen receptor-modified T (CAR-T) cell therapies for B-cell malignancies are immunocompromised and at risk for serious infections. Vaccine immunogenicity is unknown in this population. We conducted a prospective observational study of the humoral immunogenicity of 2019–2020...

Descripción completa

Detalles Bibliográficos
Autores principales: Walti, Carla S., Loes, Andrea N., Shuey, Kiel, Krantz, Elizabeth M., Boonyaratanakornkit, Jim, Keane-Candib, Jacob, Loeffelholz, Tillie, Wolf, Caitlin R., Taylor, Justin J., Gardner, Rebecca A., Green, Damian J., Cowan, Andrew J., Maloney, David G., Turtle, Cameron J., Pergam, Steven A., Chu, Helen Y., Bloom, Jesse D., Hill, Joshua A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132269/
https://www.ncbi.nlm.nih.gov/pubmed/34013294
http://dx.doi.org/10.1101/2021.05.10.21256634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132269/
https://www.ncbi.nlm.nih.gov/pubmed/34013294
http://dx.doi.org/10.1101/2021.05.10.21256634

Ejemplares similares